Inspire Medical Systems

▲ Bull Case

• ◆Reimbursement disruption is temporary, not structural. CPT code transition has scheduled resolution (AMA Cat I code Jan 2028); WISeR is 6-state pilot historically subject to modification. Q1 2026 beat consensus ($204.6M vs. ~$200M) despite full headwind; gross margin at record 86.5%. Recovery to $1.0B+ revenue by 2027 and $1.2B+ by 2028 achievable.
• ◆Operating leverage thesis remains intact. SG&A leverage drove op income from -$40M (2023) to +$51M (2025) on $288M revenue. Same fixed salesforce levered against $1.2B–$1.4B revenue by 2028–2030 generates 20–26% adjusted operating margins, comparable to ResMed.
• ◆Buyback + international growth backstop per-share economics. $200M buyback at ~$43 retires ~16% of float; international growing 15–20% (~30%+ of revenue by 2028); installed base (~120K patients) approaching IPG replacement cycle (~$10–15K/unit, growing annuity).

▼ Bear Case

• ◆GLP-1 drugs structurally compress addressable market. FDA-approved Zepbound/Wegovy for OSA (2025) showed ~50% AHI reduction in obese patients. If penetration reaches 25–35% in obese OSA over 5 years, Inspire's addressable pool shrinks 15–20% permanently, capping long-run revenue at $700–800M, intrinsic value at ~$30.
• ◆CPT code resolution may be partial or permanent at lower fees. New Cat I CPT code (expected Jan 2028) may set physician fees 20–30% below pre-transition baseline, structurally reducing physician adoption incentive. WISeR could expand to additional states. Result: 2027 revenue stays below $900M, 2028 leverage thesis breaks.
• ◆Reverse operating leverage + SBC overhang. SG&A at ~69% of revenue is fixed; $87M revenue decline in 2026 triggers ~$50M operating income decline. SBC at ~$130M/yr (14% of revenue) keeps GAAP losses persistent; $105M cash limits buyback execution to FCF cadence. Net dilution may not be fully offset.

“Central debate is 'Is 2026 a trough or a step-down?' Bulls (Leerink $116 PT, Soleus Capital ~5% position) view CPT/WISeR headwinds as identifiable policy disruptions with scheduled resolution; point to record gross margin, international resilience, asymmetric buyback as evidence underlying business intact. Bears (BofA Underperform) view GLP-1 + Nyxoah as compounding structural threats on top of policy disruption; argue CPT code may settle at permanently lower fees; contend SBC dilution makes GAAP profitability illusory. Consensus bifurcated with no dominant view — reduces groupthink risk but signals genuine analytical disagreement. Resolution gates on: (1) CPT Cat I code timeline and fee level, (2) Q2 2026 print (first full-headwind quarter), (3) Nyxoah commercial ramp (Q2–Q3 2026).”

• ◆AMA Cat I CPT code finalization (H2 2027 announcement, Jan 2028 effective) — positive if at/above prior fee → +$30–60/share
• ◆Q2 2026 earnings (August 2026) — first full-headwind quarter → +/-$10/share
• ◆WISeR program modification (6–18 months) — CMS policy reversal signal → +$10–15/share
• ◆Nyxoah commercial performance (Q2–Q3 2026 reports) — rapid ramp risk → -$10–25/share if >10% share
• ◆GLP-1 real-world OSA data (2026–2027) — actual penetration/adherence → +/-$15–25/share

• ◆CPT code permanently lower physician fees (High severity, Medium probability) — 20%+ structural fee reduction reduces adoption, permanent revenue cap
• ◆GLP-1 OSA penetration >20% by 2028 (High severity, Medium probability) — permanent TAM compression 15–20%, intrinsic value $30–40
• ◆Nyxoah Genio >10% U.S. market share by 2028 (Medium severity, Low-Medium probability) — moat erosion, ASP pressure, salesforce economics questioned
• ◆SBC dilution exceeding buyback pace (Medium severity, Medium probability) — persistent net share dilution despite $200M authorization
• ◆Inventory write-down ($30–50M) (Medium severity, Low probability) — if 2026 buildup proves strategic overstocking